RESEARCH IN AFRICA
Emerging Markets Quality Trials
Welcome to eMQT, where AFRICAN LIVES MATTER! We are the bridge between the pharmaceutical industry and Africa, utilising research healthcare experts and technology innovation to provide access to patients and high quality evidence based patient data.
- Currently, 95% of cancer patients in Sub-Saharan Africa (SSA) are diagnosed too late.
- The population offers drug naïve patients in multiple disease areas that are accessible through careful planning and engagement.
- The ‘Rising Billion’ people in Africa are expected to reach 3-5 billion by 2050 representing half of the world’s population. The rising GDP and consumer power offers an attractive therapeutic market.
- Although the patients of African descent make up 17% of the world’s population (over 1Billion), Black People are underrepresented in clinical trials globally reported as less than 3% by the Genome-Wide Association Studies (GWAS).